Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.20.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Cash flows from operating activities:    
Net loss $ (12,276) $ (11,023)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 725 1,093
(Recovery of) provision for bad debts (216) 388
Stock-based compensation expense 617 197
Deferred income taxes 186 (203)
Realized and unrealized foreign currency transaction loss 1,641 1,340
Other (3) 67
Changes in operating assets and liabilities:    
Accounts receivable 6,332 8,482
Unbilled receivables 2,345 (6,598)
Inventory   726
Prepaid expenses and other current assets and other assets 291 196
Accounts payable (1,290) 1,350
Accrued expenses and other liabilities (2,814) (2,463)
Deferred revenue (1,084) (1,590)
Net cash used in operating activities (5,546) (8,038)
Cash flows from investing activities:    
Purchases of property and equipment (202) (153)
Cash paid for acquisitions, net   (3,838)
Purchases of marketable securities   (823)
Proceeds from sales and maturities of marketable securities 2,476 1,593
Net cash provided by (used in) investing activities 2,274 (3,221)
Cash flows from financing activities:    
Proceeds from issuance of common stock 137 9
Repurchases of common stock (80) (142)
Proceeds from Paycheck Protection Program 2,413  
Net cash provided by (used in) financing activities 2,470 (133)
Effect of exchange rate on cash and cash equivalents (840) 277
Net decrease in cash, cash equivalents and restricted cash (1,642) (11,115)
Cash, cash equivalents and restricted cash at beginning of period 9,297 20,317
Cash, cash equivalents and restricted cash at end of period 7,655 9,202
Supplemental disclosure of cash flow information    
Income taxes paid 92 76
Non-cash activities:    
Purchases of property and equipment included in accounts payable   58
Right-of-use assets obtained in exchange for lease obligations $ 987 2,048
Fair value of common stock issued in acquisition   $ 874